ELUSYS & BIODEFENSE
Elusys has been working in partnership with the US Government on development of biowarfare countermeasures since 1999. The Company has received over $200M in government funding from the DoD, the National Institutes of Health (NIH) and BARDA of HHS to advance ETI-204, an anti-toxin in development for the treatment and prophylaxis of anthrax infection, towards FDA licensure and procurement into the SNS.
Most recently, Elusys has been awarded two advanced development contracts. One supports final nonclinical and clinical development and commercial-scale manufacturing for ETI-204 and the second supports evaluation of the safety and efficacy of ETI-204 when delivered IM. We have built a strong management and development team with experience in all facets of drug development. We are proud that we have met all our contract goals and milestones and have received outstanding ratings from the government as a subcontractor.
Over the past 10 years, Elusys has continued to play a key role in working with the government to improve further our nation’s ability to develop and stockpile effective countermeasures.